Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab C ases of lymphoma and tuberculosis (TB) have been described in patients receiving tumour necrosis factor a (TNFa) inhibitors. 1 2 We report a case of chronic myeloid leukaemia (CML) and TB, where molecular markers could be followed in a rheumatoid patient treated with infliximab.
CASE REPORT
A 56 year old white woman, with a 2 year history of refractory and destructive rheumatoid arthritis (RA), had been treated with methotrexate (MTX, 10 mg/week). As this was not effective, MTX was increased to 15 mg/week, and she received a total amount of about 1250 mg. Because of persistent active disease and high erythrocyte sedimentation rate (44 mm/1st h) with high platelet count at 0.6610 12 /l, infliximab was combined with MTX (15 mg/week) in August 2001 at 3 mg/kg every 8 weeks. 3 It should be noted that at that time TB prophylaxis before starting anti-TNFa treatment was not yet organised as it is today.
Although the disease improved, thrombocytosis, first considered as possibly related to inflammation, increased up to 1.1610 12 /l in January 2002. Bone marrow aspiration demonstrated typical features of CML with the (9; 22) (q34; q11) translocation. Infliximab was stopped. After a month of treatment with hydroxycarbamide (500 mg, three times a day), the platelet count decreased to 0.5610 12 /l. Hydroxycarbamide was stopped and interferon alfa (IFNa) was started in April 2002 at 8 million units a day, until August 2002. Such treatment was not well tolerated, and a weight loss of more than 10% of body weight, mild fever, and persistent bronchitis ensued, which were first thought possibly to be related to the IFNa.
In June 2002, because of cachexia and lung symptoms a chest x ray examination was carried out, which showed extensive caverns of typical TB. Some of these lesions were already evident on a film taken in 1993, strongly suggesting that the TB had been reactivated in a patient who should have received antibiotics before starting infliximab. Mycobacterium tuberculosis was grown from three consecutive sputum analyses. A four drug regimen was initiated for 2 months, followed by isoniazide and rifampicin for 4 months. Because of persistent anorexia and depression, IFNa treatment was replaced by STI 571 at 600 mg/day. At the time of writing, the patient remains in haematological remission. Joint manifestations are limited to arthralgia, treated with non-steroidal anti-inflammatory drugs.
Bcr-abl transcript was detected by reverse transcriptasepolymerase chain reaction at the time of CML diagnosis at a level of 0.5610
22 . This level decreased with myelosuppressive agents to 0.5610
24 . In addition, using RNA collected from this patient before infliximab treatment, the transcript could be detected at 0.5610 23 before the first infusion, indicating that CML was present before infliximab treatment. Its rate of expression appeared to increase during infliximab treatment, suggesting that such treatment has an effect on clonal expansion, although the mutation was already detected before treatment was started (fig 1) .
To our knowledge, this is the first description of a diagnosis of CML during infliximab treatment. 4 Available data are insufficient to draw conclusions as to whether CML developed as part of the natural history of the underlying medical conditions, or whether it occurred as a complication related to a cell mediated immune defect. 
Letters
The simultaneous occurrence of TB suggests that this patient had a cell mediated immune defect because she developed TB quickly after the initiation of infliximab treatment as for the other anti-TNF related cases. 2 To explore the systemic immune function, a bioassay based on the induction of IFNc production by interleukin (IL) 12 and/or IL18 used peripheral blood mononuclear cells (PBMC) from this patient, 15 patients with RA, and 14 healthy controls. 6 PBMC from this patient were collected during treatment for TB and CML (September 2002) and were stimulated or not with IL12 (1 ng/ml) and IL18 (5 ng/ml) for 7 days. In comparison with the controls, the patient showed a reduced production of IFNc in response to IL12 and IL18, which are key factors for a Th1 response (fig 2) . This in vitro finding suggests the presence of a systemic immune defect as reflected by an acute TB reactivation. In this particular patient the additional contribution of CML and its treatment has to be considered.
DISCUSSION
Screening for TB, as would be done today in this particular case, should have prevented the severe reactivation seen here. Although such a procedure has been particularly effective, the long term immunosuppressive effects of infliximab are unknown. Infliximab treatment is still too recent for a full assessment of its long term safety to be made, and postmarketing follow up is required to define its long term effect on malignancies, particularly on lymphomas and leukaemias. S jögren's syndrome (SS) is an autoimmune disease characterised by lymphocytic infiltration into the lachrymal and salivary glands, leading to dry eyes and mouth. Infiltration is also found in the kidneys, lungs, thyroid, and liver. Immunohistochemical studies have shown that most infiltrating lymphocytes around the labial salivary and lachrymal glands, and kidneys are CD4 positive ab T cells. Previous studies with polymerase chain reaction provide evidence about the T cell receptor Vb and Va genes on these T cells, and sequence analysis of the CDR3 region indicates some conserved amino acid motifs, supporting the notion that infiltrating T cells recognise relatively few epitopes on autoantigens. 1 Candidate autoantigens recognised by T cells infiltrating the labial salivary glands of patients with SS have been analysed, and Ro/SSA 52 kDa, a-amylase, heat shock protein, and T cell receptor BV6 2 have been identified. However, there is no direct evidence that these reactive T cells really attack and destroy the salivary glands. In contrast, the presence of autoantibodies (Abs) against M3 muscarinic acetylcholine receptor (M3R) has been reported, and it is suggested that an immune reaction to M3R plays a crucial part in the generation of SS. [3] [4] [5] Robinson, et al demonstrated that human anti-M3R Abs reduce the secretory function in NOD.Igmnull mice. 3 Moreover, Bacman et al clearly showed that human Abs against the second extracellular loop of M3R could
